You want to know one thing: when does this start working? Fair question. It’s the question everyone asks, and it’s the one the marketing lies about most. So here’s the plain version, one compound at a time, plus the honest bit nobody puts on the label: for most of these, there is no real timeline, because there isn’t enough human research to build one. “Nobody knows yet” is sometimes the truest answer you’ll get, and you should be wary of anyone who claims otherwise.
Read this before you spend a cent expecting results on a schedule. It’ll save you the money and the letdown.
The rule that decides everything else
Here’s the thing that sorts these five compounds into two very different piles: a real timeline needs real human trials, and only one of the five has them.
That one is PT-141 (the desire drug). It went through two large randomized trials in roughly 1,247 premenopausal women and got FDA approval as Vyleesi, for one specific use [1][2]. The other four, glutathione, GHK-Cu, BPC-157, and MOTS-c, sit somewhere between “weak evidence” and “basically no human data at all.” So if you see a promise like “you’ll notice results in three weeks” attached to any of those four, that number didn’t come from a lab. It came from a sales page.
Think of it like a traffic light as you read on:
- Green (real, studied effect): PT-141
- Yellow (some evidence, slow and modest): glutathione, topical GHK-Cu
- Red (no honest human timeline exists): BPC-157, MOTS-c
Keep that light in your head. It’ll save you from treating a guess like a guarantee.
PT-141: it’s a per-dose thing, not a slow build
This is the only one with real data behind it, and its timeline works differently than most people expect.
PT-141 isn’t something you take every day and wait weeks for. Used as approved, you take it ahead of anticipated activity, and it works on brain pathways tied to desire rather than building up in your body over time [2]. So think per-dose, not per-month. In the trials (called RECONNECT), women with hypoactive sexual desire disorder saw a statistically real improvement in desire and less distress about it, compared to placebo, over the treatment period [1].
Translate that honestly: the effect was real, and it was modest. This isn’t a switch that flips desire on. It helped a meaningful number of women in this specific group, to a measurable but moderate degree, not a dramatic one. And on that same per-dose timeline, expect the known side effects too: nausea, flushing, and headache were the common ones [1]. You might notice the nausea before you notice anything you’d call a benefit. So set your expectations at “modest, as-needed, possible queasiness,” not “life-changing.”
Glutathione: weeks at best, and it doesn’t stick
Glutathione gets sold for skin brightening, usually as a capsule, IV drip, or injection, with a strong hint that you’ll see a visible, predictable glow. The human research doesn’t back that confidence up.
A review of three randomized controlled trials on systemic glutathione as a skin-whitening agent concluded it’s “not beneficial enough,” because it only worked in certain areas of the body, only in certain age groups, and didn’t last [5]. So the honest timeline, if you notice anything at all, is: a modest change over a stretch of weeks, patchy across your body, gone once you stop. One of those three trials actually landed against it. Translate that: don’t count on a visible result, don’t expect it evenly, and know that whatever shows up won’t stay. “Glow from within in 30 days” is running ahead of what the evidence says.
GHK-Cu: think skincare, not medicine
GHK-Cu is the copper peptide behind a lot of “peptide serum” marketing, sold for firmer skin, fewer fine lines, and hair support. Its evidence is real, but narrow, and the timeline matches what you’d expect from a good skincare ingredient, not a fast-acting drug.
The main review on it describes GHK-Cu as a naturally occurring copper-binding tripeptide that boosts collagen and supports wound repair, with cosmetic studies linking it to better skin laxity, elasticity, and fewer fine lines [3]. Skin remodeling is slow. If you’re using a topical GHK-Cu product, expect gradual change over weeks to months of steady use, the way you’d expect from any serious skincare ingredient, not overnight. Two things to keep in your back pocket: most of the strongest evidence here is cosmetic and mechanism-based rather than from big clinical trials, and injectable GHK-Cu sold for systemic anti-aging is a completely different claim with far less backing. Topical: slow and modest. Injectable, systemic: unproven.
BPC-157: there’s no honest timeline to give you
Here’s the one you most need to hear straight. There is no evidence-based human timeline for BPC-157, because the human evidence barely exists.
A 2025 narrative review of BPC-157 for musculoskeletal healing found only three small human pilot studies, called the human data “extremely limited,” and said plainly that “until well-designed human trials are conducted and published, BPC-157 should not be recommended for clinical use” [4]. Read that twice, because it’s really the whole answer. Nobody can tell you, from real evidence, how long BPC-157 takes to do anything, because the studies that would answer that haven’t been run. Any page promising you healing on a schedule is making that schedule up. The honest expectation isn’t a number of weeks. It’s “this is investigational, and anyone giving you a timeline is guessing.”
MOTS-c: interesting science, no human clock
MOTS-c is the metabolic peptide, marketed for fat loss, metabolism, and anti-aging. Like BPC-157, there’s no human timeline you can trust here.
The research describes MOTS-c as a mitochondrial-derived peptide that acts on muscle and glucose metabolism through the AMPK pathway, with implications for obesity, diabetes, and exercise, and notes exercise itself raises your own MOTS-c levels [6]. That’s genuinely interesting biology. It’s also almost entirely animal and cell studies. There’s no approved MOTS-c product and no controlled human trial proving its metabolic benefits in people, let alone how fast they’d show up. So treat it the same way as BPC-157: investigational, no human-backed timeline, and healthy skepticism toward any specific promise.
The checklist: how to tell “it’s working” from “I wanted it to work”
Here’s the part that actually protects you once your expectations are realistic. With compounds this thinly studied, your own gut feeling is a shaky witness. You wanted a result, you paid for a result, and that combination alone can convince you one showed up. So don’t trust vibes. Track it.
Write down: – the date – the exact amount you took – your weight – your blood pressure, if PT-141 is in the mix – any change you notice, whether it seems good or just odd
Then look back at the record instead of trusting memory. This one habit does more than anything else to separate a real response from wishful thinking, because a written log doesn’t flatter you the way memory does. The trials that gave us what little we know tracked everything carefully. Borrow that habit. If you’re working with a clinician, a real log turns a check-in into something useful instead of a guessing game. A notebook is enough.
And set your window in advance. Decide how long you’ll try something and what would actually count as a result, then stick to it. That stops you quitting too soon, or (far more common) staying on something for months that was never doing anything, kept going by hope and a well-written sales page.
The choice, laid out plainly
Put the timelines side by side and the picture is simple. PT-141 gives you a real but modest, as-needed effect, with a real chance of nausea before anything else [1][2]. Glutathione, if it does anything, works slowly, unevenly, and temporarily [5]. Topical GHK-Cu works gradually over weeks to months, like decent skincare, while the injectable version is unproven [3]. BPC-157 and MOTS-c have no honest human timeline at all, because the studies that would give us one don’t exist yet [4][6]. Anyone selling you a confident schedule for those last two is making it up.
If you decide to go ahead with any of this, do it with realistic expectations and someone holding you accountable, not a marketing calendar. That means a licensed clinician who can screen you for things that actually matter, like the cardiovascular warning on PT-141’s approved label: it temporarily raises blood pressure and lowers heart rate after each dose, and it’s not for people with uncontrolled high blood pressure or known heart disease [2], and someone who asks the pregnancy questions before anything gets dispensed. FormBlends is one provider that runs that kind of supervised, prescription-based model, rather than mailing you a research chemical with an invented timeline taped to it. What that setup actually buys you is a real person accountable for the decision and the follow-up, which is worth more than a promise of results by next month.
The honest bottom line: expect modest from the one drug with real evidence behind it, expect slow and patchy from the cosmetic ones, and expect nothing on a trustworthy schedule from the investigational ones. Track what actually happens to you. Let the log, not the sales copy, tell you whether it’s working.
Questions people actually ask
Which of these actually has a real, studied timeline? Only PT-141 (bremelanotide). It’s the single compound here tested in large randomized human trials and approved as Vyleesi, so it has a documented response pattern [1][2]. Glutathione, GHK-Cu, BPC-157, and MOTS-c don’t have that level of human evidence, so any specific “results in X weeks” claim about them is coming from marketing, not trial data.
How fast does PT-141 work, is it a daily build-up thing? No, it’s not a build-up. Used as approved, you take it ahead of anticipated activity and it acts on desire-related brain pathways rather than accumulating in your system, so think per-dose, not per-month [2]. Expect a real but modest effect, and expect common side effects like nausea, flushing, and headache, sometimes showing up before any benefit does [1].
How long until glutathione actually lightens or brightens skin? Honestly, don’t count on it. A review of three randomized controlled trials on systemic glutathione for skin whitening called it “not beneficial enough,” since any effect only showed up in certain areas and age groups and didn’t last after stopping [5]. If you see anything, expect it to be modest, uneven, and temporary, not a reliable 30-day glow.
How long before topical GHK-Cu shows a difference? Plan on weeks to months of consistent use, same as any decent skincare ingredient. The main review describes it as a copper-binding tripeptide that boosts collagen and supports skin repair, with cosmetic improvements in elasticity and fine lines [3]. Skin remodeling is slow, so expect gradual change if you’re using it topically, and treat injectable, systemic claims as unproven.
Why won’t anyone give me a timeline for BPC-157 or MOTS-c? Because the human studies that would establish one haven’t been done. A 2025 review of BPC-157 found only three small human pilot studies, called the evidence “extremely limited,” and said it shouldn’t be used clinically until proper trials exist [4]. MOTS-c’s evidence is almost entirely animal and cell work, with no controlled human trial and no approved product [6]. Anyone giving you a confident schedule for either one is inventing it.
How do I tell a real result from wishful thinking? Keep a written log. Note the date, the exact amount taken, your weight, your blood pressure if PT-141 is involved, and anything you notice, then look back at the record instead of trusting your memory. Decide in advance how long you’ll test something and what would actually count as working. A notebook is all you need, and it won’t flatter you the way memory does.
How long before women actually notice results from peptide therapy?
Most women report the first noticeable changes somewhere between four and twelve weeks, depending on which peptide they are using and what they are trying to improve. Sleep and energy often shift earliest, sometimes within the first two to three weeks. Skin texture and body composition changes tend to take longer, closer to the eight to twelve week mark, because those involve slower biological processes like collagen synthesis and fat metabolism.
Are peptides safe for women to use?
Safety depends heavily on the specific peptide, the dose, and where it comes from. Peptides prescribed and monitored by a licensed clinician carry a very different risk profile than research-chemical versions sold online with no quality controls. Common side effects reported with peptides like BPC-157 or CJC-1295 include injection site reactions, water retention, and transient fatigue. Long-term safety data in women is still limited, so honest clinicians will tell you that upfront.
What peptides do women actually use most, and why?
The peptides women ask about most often are BPC-157 for recovery and gut issues, CJC-1295 with or without Ipamorelin for growth hormone support, and PT-141 for libido. GHK-Cu comes up frequently in skin-focused conversations. Each one works through a different mechanism, so the right choice depends on your goal, not on what is trending. A good clinician will match the peptide to your bloodwork and symptoms rather than just prescribing the popular option.
Where should women buy peptides, and what makes a source legitimate?
The safest route is through a licensed compounding pharmacy that operates under physician supervision, such as the model FormBlends uses, where formulations are third-party tested and prescribed to a specific patient. Research-chemical websites that sell peptides labeled ‘not for human use’ have no regulatory accountability and inconsistent purity. Buying from those sources means you genuinely do not know what you are injecting, and that is a real risk, not a theoretical one.
References
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
- U.S. Food and Drug Administration. VYLEESI (bremelanotide injection) Prescribing Information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987.
- Seow LJ, et al. BPC-157 for the Management of Musculoskeletal Injuries: A Narrative Review of Current Evidence. 2025.
- Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. Indian Journal of Dermatology, Venereology and Leprology. 2016;82(3):262-272.
- Merry TL, Chan A, Woodhead JST, et al. Mitochondrial-derived peptides in energy metabolism. American Journal of Physiology-Endocrinology and Metabolism. 2020;319(4):E659-E666.
Written by Saskia Delgado, staff writer. Reading the studies before believing the pitch. Last reviewed January 2026.
This is background reading, not medical guidance. Your physician should make the final call.
